{
  "docId": "019de074-15c9-703f-ba69-83bd63385db9",
  "docSlug": "61dc585c6c50f6919636d426c025da60",
  "documentTitle": "AstraZeneca | Investor Event Presentation Deck | 42 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 20,
  "pageCount": 42,
  "prevPage": 19,
  "nextPage": 21,
  "slideType": "appendix_methodology",
  "function": "present_framework",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "The diagram illustrates a randomized clinical trial flow.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-15c9-703f-ba69-83bd63385db9/20",
  "deckHref": "/decks/019de074-15c9-703f-ba69-83bd63385db9",
  "deckJsonHref": "/decks/019de074-15c9-703f-ba69-83bd63385db9.json",
  "deckAnchorHref": "/decks/019de074-15c9-703f-ba69-83bd63385db9#slide-20",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.6,
        "x": 0.35,
        "y": 0.25
      },
      "kind": "diagram",
      "text": "Randomization flow diagram showing patient population, stratification, and treatment arms.",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "05c06e76-5d55-4983-9407-b951aec9b658",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.95,
        "x": 0.03,
        "y": 0.92
      },
      "kind": "disclaimer",
      "text": "1. disease progression assessed by the Investigator and defined using RECIST, version 1.1. ABC = advanced breast cancer; CBR24 = clinical benefit rate at 24 weeks; CDK4/6i = CDK4/6 inhibitor; CT = chemotherapy; CTC: circulating tumour cells; ctDNA = circulating tumour DNA; ER = estrogen receptor; ESR1m = mutation in estrogen receptor 1 gene; ET = endocrine therapy; HER2 = human epidermal growth factor; PFS: progression-free survival; R: randomization; RECIST: Response Evaluation Criteria for Solid Tumors; SERD: selective estrogen receptor degrader.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "61f7e61d-2fd7-4e0b-a6b8-c3ca578d615d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.28,
        "x": 0.03,
        "y": 0.33
      },
      "kind": "list",
      "text": "Key inclusion/exclusion criteria: Recurrence or progression on at least one line of ET; No prior fulvestrant or oral SERD in ABC; No more than one line of ET in ABC setting; No more than one line CT in ABC setting; Measurable and non-measurable disease",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5cfb65e9-176f-404c-877a-aa64a6bead67",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.5,
        "x": 0.35,
        "y": 0.73
      },
      "kind": "list",
      "text": "Primary endpoint: PFS (investigator assessment); Secondary endpoints: CBR24, ORR, OS, Safety; Translational endpoints: serial ctDNA analysis including ESR1m, serial CTCs analysis; SERENA-2 was not powered to compare between camizestrant doses",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6941b15b-e380-4cff-aa48-9bfe8739de5c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "SERENA-2: trial design and inclusion criteria",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fdf9cccc-b7f1-43ec-af60-a2ee41615592",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.9,
        "x": 0.03,
        "y": 0.13
      },
      "kind": "title",
      "text": "A randomised, multi-dose Phase II trial of camizestrant (75mg, 150mg) vs. fulvestrant",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "45bf6a4a-efb0-44a8-9a29-75b0a8375f9d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "clinical-trial-design",
      "slug": null,
      "matchId": "12045449-ca6d-401c-b298-45d4763ac111",
      "evidence": "Standardized representation of patient randomization and study arms.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 29,
      "from": 19,
      "beatId": "a90ff87c-6a94-47ae-8622-c8e4ab68f4ea",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "SERENA-2 trial data and conclusions",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}